, the Seattle-based vaccine development organization, has announced the formation of a new center aimed at accelerating the development and introduction of lifesaving vaccines for vulnerable children and communities around the world.
With initial funding of $11 million from the , the PATH Center for Vaccine Innovation and Access will bring PATH's vaccine projects together in a single team working across every stage of the complex process of vaccine research, development, and introduction. Currently, PATH vaccine work includes more than two dozen vaccines either in development or already in use as protection against fifteen different diseases. The organization's vaccine development efforts are focused on the leading causes of child deaths worldwide — including pneumonia, diarrheal disease, and malaria — as well as global health priorities such as polio and meningitis.
"Our goal in creating this new Center for Vaccine Innovation and Access is to accelerate the development of new vaccines and help ensure that every child in the world has access to immunization," said PATH president and CEO Steve Davis. "The new center will bring together our experts across all aspects of vaccine development and delivery and enable PATH to work even more effectively with a wide range of vaccine development funders, health officials, regulators, and pharmaceutical and device manufacturers to make lifesaving vaccines available. It will also enable us to respond more effectively to new and rapidly evolving threats such as the recent Ebola and Zika outbreaks."